Previous studies have shown that co-occurring genomic events are detected in up to 93% of EGFR-mutant NSCLCs.[11] Tumor biopsies have a greater depth of molecular characterization; however, they may be spatially limited to a minute fragment of patients’ overall cancer burden. Here, EGFR is linked to neoplasm.